AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%

Study limitation reported by the research below: “Upper confidence interval for median OS in Arms A and C was 'not estimable' at data cutoff, indicating survival data may still be maturing despite the futility call.”